<div id="readability-page-1"><p>In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Elicio Therapeutics, with a price target of <span id="expert-recommendation-target">$18.00</span>.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>According to TipRanks, Roy is an analyst with an average return of <span>-17.3%</span> and a 26.41% success rate. Roy covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, CervoMed, and Cullinan Management.</p> <p>Currently, the analyst consensus on Elicio Therapeutics is a Moderate Buy with an average price target of $18.00.</p></div>

ELTX

<p>JonesTrading analyst Soumit Roy maintained a Buy rating on Elicio Therapeutics with a price target of $18.00. Roy, who covers the Healthcare sector, has an average return of -17.3% and a 26.41% success rate. The analyst consensus on Elicio Therapeutics is a Moderate Buy with an average price target of $18.00.</p>

JonesTrading Keeps Their Buy Rating on Elicio Therapeutics (ELTX)